INDEPENDENT VERDICT
Tempo Therapeutics, Inc. is a verifiable San Diego regenerative-medicine company whose September 11, 2026 Form D documents a $14.5 million private financing with an unusual feature that the later press announcement does not emphasize: the SEC filing classifies the security as Debt, not Equity. Tempo reported $14 million already sold, $500,000 remaining and 43 investors after a first sale on August 27, under Rule 506(b), with no commissions, finder fees or Item 16 related-person payments. Five days later the company publicly announced that it had closed an oversubscribed $14.5 million financing led by Galaxy Sirius Partners, with participation from Johnson & Johnson Innovation - JJDC, Gideon Strategic Partners, Mesa Verde Venture Partners, YK Bioventures and other existing and new investors. The public announcement does not characterize the instrument in the same detail, making the SEC filing important: this capital should not automatically be described as a conventional priced Series B equity round when the primary regulatory filing says Debt.
THE REAL STORY IS WHY TEMPO USED DEBT AT THIS STAGE
Tempo is raising capital at a very different point in development from its 2024 Series A. That earlier $12 million financing was explicitly presented as equity capital intended to take the company's MAP scaffold products into clinical trials, led by Galaxy-Sirius Partners and JJDC. By September 2026, the risk profile had changed: TT101 had completed its first-in-human MOSAIC study, Tempo had publicly reported positive safety and scar-quality results, and the company said it had already submitted a De Novo application to FDA for its lead surgical-reconstruction product. The newest financing therefore appears to fund a late-development and commercialization bridge rather than basic scientific validation. Debt can be attractive at this stage if investors believe a definable regulatory or commercial milestone could increase enterprise value before another equity round, but it also creates obligations that equity does not. The Form D does not disclose coupon, maturity, security interest, conversion features, warrants, repayment schedule or lender priority, so investors cannot determine from the filing whether this is straight venture debt, convertible debt or another structured security.
TT101 HAS ALREADY MOVED FROM PRECLINICAL SCIENCE INTO HUMAN DATA
Tempo's lead product is based on Microporous Annealed Particle, or MAP, technology: injectable synthetic microgel particles that flow into an irregular defect and then anneal into a porous scaffold intended to support cellular infiltration, vascularization and formation of new tissue. Unlike a cell therapy or biologic implant, TT101 is described as a stand-alone synthetic material without cells or biologic growth factors, which is central to Tempo's commercial thesis because the product is intended to provide a regenerative physical microenvironment rather than deliver living cells. The MOSAIC first-in-human study evaluated MAP Wound Matrix in 40 patients with full-thickness wounds following Mohs surgery for non-melanoma skin cancer. Tempo reported that the trial met its primary safety endpoint, with no serious adverse device effects, infections or delayed wound healing in the MAP arm; the company also reported that treated wounds achieved a favorable wound-bed score roughly 14 days earlier than controls and showed better physician-assessed scar quality at approximately six months. The original study protocol makes clear that this was a first-in-human safety study and was not designed as a fully powered pivotal efficacy trial, which is an important limitation when interpreting the company's positive results.
DE NOVO SUBMISSION CHANGES THE CENTRAL DILIGENCE QUESTION
The September financing announcement states that Tempo has submitted its lead MAP product to FDA through the De Novo pathway. That is a meaningful regulatory transition because a De Novo request is used when a novel device does not have an appropriate predicate for a traditional 510(k), and clearance or classification could establish a new regulatory category for the technology. However, submission is not clearance. The public record reviewed confirms that Tempo has filed the application and completed the supporting first-in-human trial, but it does not establish that FDA has accepted the request for substantive review, agreed with every proposed indication, granted marketing authorization or accepted every clinical claim used in company materials. The latest financing therefore sits in the gap between clinical validation and regulatory approval. Investors should obtain the actual De Novo submission scope, proposed indication for use, FDA correspondence, outstanding questions, manufacturing-validation status, sterility and shelf-life data, reimbursement strategy and commercial-launch timeline rather than assuming that submission itself makes commercialization imminent.
MAP IS A PLATFORM, BUT TT101'S SUCCESS DOES NOT AUTOMATICALLY VALIDATE EVERY APPLICATION
Tempo's long-term thesis extends well beyond post-Mohs wound repair. Its official technology materials describe MAP as a platform capable of being adapted for surgical reconstruction, abdominal-wall applications, drug delivery, cell engraftment and next-generation vaccine technologies, while the 2026 financing announcement says some proceeds will also support clinical work in regenerative aesthetics, including tissue changes associated with weight loss and healthy aging. Tempo also has a substantial research history behind the platform: academic work involving founders and collaborators has explored immune polarization, stroke repair, myocardial infarction and other regenerative applications, and public patent records show Tempo-owned applications covering manufacturing and microgel-scaffold systems. Government funding has also played a role in the platform's development, including NIH and NSF SBIR/STTR awards for diabetic wounds, first-in-human tissue regeneration and MAP-based vaccine concepts. Those broader programs demonstrate platform depth, but they should not be folded into TT101's regulatory status; each indication can require its own formulation, evidence, regulatory pathway and commercial economics.
FINAL ASSESSMENT
Tempo Therapeutics' 2026 financing is distinctive because the company is no longer raising money simply to reach human testing. SEC EDGAR confirms a $14.5 million Debt offering with $14 million sold to 43 investors as of September 11, while Tempo announced the completed $14.5 million financing on September 16 after reporting first-in-human results and an FDA De Novo submission. At the same time, leadership shifted: Eric Richman became Interim CEO, Steven Sands became Chairman, founder Westbrook Weaver moved into the Chief Technology Officer role and Don Griffin became Chief Scientific Officer. That combination of debt financing, regulatory submission and management transition suggests a company moving from founder-led technology development toward a more commercialization-oriented operating phase.
The core independent finding is therefore not simply that Tempo raised another $14.5 million. It is that a biomaterials company which raised equity in 2024 to enter human trials is now using debt after producing initial human data and submitting its first De Novo application. That can reduce near-term equity dilution if the next regulatory milestone is successful, but it also means investors should understand the debt terms and runway much more carefully. The next critical documents are the debt instruments themselves, FDA correspondence, audited cash position, burn rate, manufacturing scale-up plan, final commercial indication, reimbursement strategy and TT101 launch economics. Form D verifies capital formation; it does not establish that FDA clearance, reimbursement or commercial adoption will follow.
Form D is an exempt-offering notice. It is not SEC approval of Tempo Therapeutics, MAP technology, TT101, the De Novo application, the financing terms or any investment return.
SEC SNAPSHOT
ISSUER: Tempo Therapeutics, Inc. | CIK: 0001813688 | SEC FILE NO.: 021-597176 | FILM NO.: 261373281 | ACCESSION NO.: 0001813688-26-000003 | FILED / EFFECTIVE: September 11, 2026
ENTITY: Delaware Corporation | ORGANIZED: More than five years ago | PRINCIPAL ADDRESS: 3030 Bunker Hill Street, Suite 308, San Diego, CA 92109 | PHONE: 619-202-7445
INDUSTRY: Biotechnology | EXEMPTION: Regulation D Rule 506(b) | POOLED INVESTMENT FUND: No | INVESTMENT COMPANY ACT EXCLUSION: None claimed
SECURITY: Debt | BUSINESS COMBINATION: No | FIRST SALE: August 27, 2026 | OFFERING DURATION: One year or less
TOTAL OFFERING: $14,500,000 | AMOUNT SOLD: $14,000,000 | REMAINING: $500,000 | INVESTORS: 43 | MINIMUM INVESTMENT FIELD: $0
SALES COMMISSIONS: $0 | FINDER FEES: $0 | ITEM 16 RELATED-PERSON PAYMENTS: $0 | REVENUE RANGE: Declined to disclose
RELATED PERSONS: Westbrook Weaver — Executive Officer / Director | Donald Griffin — Director | Biren Mehta — Director | Steven Sands — Director | Eric Richman — Executive Officer / Director
FORM D SIGNATORY: Eric Richman | TITLE: Chief Executive Officer
PUBLIC SEPTEMBER 16 FINANCING ANNOUNCEMENT: $14.5M oversubscribed financing | lead investor: Galaxy Sirius Partners | other named participants: Johnson & Johnson Innovation - JJDC, Gideon Strategic Partners, Mesa Verde Venture Partners, YK Bioventures and other new/existing investors.
IMPORTANT SECURITY-TYPE DISTINCTION: The company press release describes a $14.5M financing but the September 11 Form D specifically identifies the security as DEBT. It should therefore not automatically be labeled a priced equity round or Series B without separate transaction documentation.
2024 SERIES A CONTEXT: Tempo publicly announced a $12M Series A equity financing led by Galaxy-Sirius Partners and JJDC to advance MAP scaffold products into clinical trials.
LEAD PRODUCT: TT101 / MAP Wound Matrix | TECHNOLOGY: Microporous Annealed Particle synthetic regenerative scaffold.
FIRST-IN-HUMAN TRIAL: MOSAIC / NCT06600152 | 40 patients according to Tempo's 2026 financing announcement | post-Mohs full-thickness surgical wounds.
PUBLICLY REPORTED CLINICAL RESULTS: Primary safety endpoint met | no serious adverse device effects, infections or delayed wound healing reported by Tempo | favorable Wound Bed Score reached approximately 14 days earlier than control | improved physician-assessed scar quality at approximately six months.
TRIAL LIMITATION: The original clinical protocol characterizes MOSAIC as a first-in-human safety study and states it was not statistically powered as a pivotal efficacy trial.
FDA STATUS: Tempo states that its lead product has been submitted through the FDA De Novo pathway. Submission is not equivalent to clearance or approval.
2026 LEADERSHIP TRANSITION: Eric Richman — Interim CEO | Steven Sands — Chairman | Westbrook Weaver — Co-Founder / CTO | Don Griffin — CSO / Director.
PLATFORM EXTENSIONS UNDER PUBLIC DEVELOPMENT: surgical reconstruction | wound healing | regenerative aesthetics | drug delivery | cell engraftment | vaccine applications. These broader programs should not be treated as FDA-cleared uses of TT101.
CORE INDEPENDENT FINDING: Tempo's 2026 capital structure reflects a transition from clinical-entry financing to regulatory/commercialization financing. After using equity to enter human trials in 2024, the company now reports a $14.5M debt offering after positive first-in-human results and an FDA De Novo submission. The key investment issue is no longer whether MAP can reach humans, but whether the debt-funded bridge provides enough runway to obtain regulatory clearance, scale manufacturing and convert a novel biomaterial platform into a commercially reimbursed surgical product.
Form D is an exempt-offering notice and is not an SEC-issued certificate, approval or endorsement.